| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
TAK-448 acetate targets the KISS1 receptor (KISS1R/GPR54), a GPCR involved in the regulation of reproduction, endocrine function, and cancer progression. Upon administration, TAK-448 binds to KISS1 receptors located in the hypothalamus, influencing the release of luteinizing hormone and follicle-stimulating hormone.
|
|---|---|
| ln Vitro |
TAK-448 acetate is a potent KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM. It demonstrates high potency in activating the KISS1 receptor, making it a valuable tool for studying KISS1R signaling and reproductive endocrinology. The compound inhibits the proliferation of VCaP cells.
|
| ln Vivo |
In the VCaP xenograft model, TAK-448 acetate salt (0.01-3 mg/kg; ih medication; day 0 and day 28 drug) exhibits more potent anti-tumor actions [2].
In the VCaP xenograft model, TAK-448 acetate (0.01–3 mg/kg; intrahypothalamic administration; days 0 and 28) exhibits more potent anti-tumor actions. The compound has been studied for its role in modulating the hypothalamic-pituitary-gonadal axis and influencing hormonal levels, making it of interest in both cancer research and endocrinology. |
| Enzyme Assay |
For receptor binding assays, membranes from cells expressing KISS1R are incubated with radiolabeled ligands (e.g., [¹²⁵I]-kisspeptin) and varying concentrations of TAK-448 acetate. Specific binding is determined, and IC50 values are calculated from competition curves.
|
| Cell Assay |
Cellular assays are performed using cells expressing KISS1R (e.g., CHO or HEK293 cells transfected with KISS1R). Cells are treated with TAK-448 acetate at various concentrations, and receptor activation is measured by calcium mobilization assays using fluorescent calcium indicators (e.g., Fluo-4) or by measuring downstream signaling (e.g., ERK phosphorylation by Western blot). EC50 values are calculated from dose-response curves.
|
| Animal Protocol |
Animal/Disease Models: Rat VCaP xenograft androgen-sensitive prostate cancer model (7weeks old rats)
Doses: 0.01, 0.03, 0.3, 3 mg/kg Route of Administration: administered every other day; administered on days 0 and 28 Drug Experimental Results: Greater anti-tumor effect in VCaP xenograft model. In the VCaP xenograft model (androgen-sensitive prostate cancer), rats are implanted with VCaP cells and treated with TAK-448 acetate at doses of 0.01, 0.03, 0.3, or 3 mg/kg via intrahypothalamic administration on days 0 and 28. Tumor volume is measured over time. Anti-tumor efficacy is evaluated by comparing tumor growth between treated and control groups. Hormonal levels are measured by ELISA or RIA. |
| ADME/Pharmacokinetics |
TAK-448 acetate has a molecular weight of 1285.41. As a synthetic peptide, it is administered parenterally (intrahypothalamic or subcutaneous) for in vivo studies. The compound is likely metabolized through proteolytic degradation and has a relatively short half-life in circulation. The acetate salt form improves solubility and stability.
|
| Toxicity/Toxicokinetics |
TAK-448 acetate has demonstrated a favorable safety profile in preclinical studies. At effective doses (0.01–3 mg/kg), the compound is well-tolerated in animal models. No significant toxicity has been reported at the doses used in xenograft studies.
|
| References |
|
| Additional Infomation |
TAK-448 acetate is a potent and full KISS1R agonist with an IC50 of 460 pM and an EC50 of 632 pM. It exhibits anti-tumor activity in VCaP xenograft models and modulates the hypothalamic-pituitary-gonadal axis. It is a synthetic peptide also known as MVT-602 acetate.
|
| Molecular Formula |
C60H84N16O16
|
|---|---|
| Molecular Weight |
1285.40657329559
|
| Exact Mass |
1284.625
|
| CAS # |
1470374-22-1
|
| Related CAS # |
TAK-448;1234319-68-6
|
| PubChem CID |
91668185
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
18
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
31
|
| Heavy Atom Count |
92
|
| Complexity |
2470
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
O[C@H]1CN(C([C@@H](CC2C=CC(=CC=2)O)NC(C)=O)=O)[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NNC(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC2=CNC3C=CC=CC2=3)=O)CCCN/C(=N/C)/N)=O)CC(C)C)=O)=O)CC2C=CC=CC=2)=O)[C@@H](C)O)=O)CC(N)=O)=O)C1.OC(C)=O
|
| InChi Key |
ITKNOAGWRWNSIK-NHDJLUSCSA-N
|
| InChi Code |
InChI=1S/C58H80N16O14.C2H4O2/c1-30(2)22-42(51(82)66-40(16-11-21-63-57(61)62-5)50(81)67-41(49(60)80)25-35-28-64-39-15-10-9-14-38(35)39)70-58(88)73-72-53(84)43(23-33-12-7-6-8-13-33)69-55(86)48(31(3)75)71-52(83)44(27-47(59)79)68-54(85)46-26-37(78)29-74(46)56(87)45(65-32(4)76)24-34-17-19-36(77)20-18-34;1-2(3)4/h6-10,12-15,17-20,28,30-31,37,40-46,48,64,75,77-78H,11,16,21-27,29H2,1-5H3,(H2,59,79)(H2,60,80)(H,65,76)(H,66,82)(H,67,81)(H,68,85)(H,69,86)(H,71,83)(H,72,84)(H3,61,62,63)(H2,70,73,88);1H3,(H,3,4)/t31-,37-,40+,41+,42+,43+,44+,45-,46+,48+;/m1./s1
|
| Chemical Name |
(2S)-2-[[(2S,4R)-1-[(2R)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]-4-hydroxypyrrolidine-2-carbonyl]amino]-N-[(2S,3R)-1-[[(2S)-1-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-5-[(N'-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamoyl]hydrazinyl]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]butanediamide;acetic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~77.80 mM)
H2O : ~50 mg/mL (~38.90 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (1.94 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (1.94 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: 100 mg/mL (77.80 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.7780 mL | 3.8898 mL | 7.7796 mL | |
| 5 mM | 0.1556 mL | 0.7780 mL | 1.5559 mL | |
| 10 mM | 0.0778 mL | 0.3890 mL | 0.7780 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
